1, 2009 reflected cash and cash equivalents of $2.3 million and stockholders' equity of $3.6 million. The Company has no outstanding debt. The Company's latest financials have been prepared on a going concern basis. As previously disclosed, Encorium's independent registered public accounting firm reported that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 27, 2009, contains a paragraph that indicates that, while the Company's financial statements have been prepared on a going concern basis, there is substantial doubt about its ability to continue as a going concern, and that no adjustments have been made to the financial statements that might result from the outcome of this uncertainty.
In the event the sales described above are not consummated, the Company anticipates it will be able to meet its cash requirements at least into the first quarter of 2010 assuming it is able to fully implement its cost cutting initiatives, win additional contracts during fiscal 2009 and maintain current customer contracts. If the Company is unable to fully implement its cost cutting initiatives, win additional contracts during fiscal 2009 and maintain current customer contracts, it will need additional capital, which it may not be able to raise on terms acceptable to it or at all, and may need to significantly reduce operating costs, which may include the cessation of operations in some countries.
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical anPage: 1 2 3 4 5 6 7 8 9 Related medicine news :1
. Encorium Group Enters into Non-Binding Letters of Intent2
. Encorium Reports Fourth Quarter and Full Year 2008 Financial Results3
. Encorium Announces Receipt of Letter from Nasdaq Regarding its 2008 Form 10-K Filing4
. Encorium Appoints Shahab Fatheazam to its Board of Directors5
. BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels6
. Escalon(R) Reports Third Quarter Fiscal 2009 Results7
. Encision Reports Fourth Quarter and Fiscal Year 2009 Results8
. BMP Sunstone Reports First Quarter 2009 Financial Results9
. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results10
. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 200911
. AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results